Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.

Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov; 32(11):1940-1949.

View in: PubMed

collapse authors with profiles